The DOI matches its Crossref record.
Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers
Open accessAbstract
Background: Colorectal, endometrial and upper urinary tract tumours are characteristic for Lynch syndrome (hereditary non-polyposis colon carcinoma, HNPCC). The aim of the present study was to establish whether carriers of mutations in mismatch repair genes MLH1, MSH2 or MSH6 are at increased risk of urinary bladder cancer. Methods: Carriers and first degree relatives of 95 families with a germline mutation in the MLH1 (n=26), MSH2 (n=43), or MSH6 (n=26) gene were systematically questioned about the occurrence of carcinoma. The cumulative risk of cancer occurring before the age of 70 years (CR70) was compared to the CR70 of the general Dutch population. Microsatellite instability (MSI) testing and/or immunohistochemistry (IHC) for mismatch repair proteins was performed on bladder tumour tissue. Results: Bladder cancer was diagnosed in 21 patients (90% men) from 19 Lynch syndrome families (2 MLH1, 15 MSH2, and 4 MSH6). CR70 for bladder cancer was 7.5% (95% CI 3.1% to 11.9%) for men and 1.0% (95% CI 0% to 2.4%) for women, resulting in relative risks for mutation carriers and first degree relatives of 4.2 (95% CI 2.2 to 7.2) for men and 2.2 (95% CI 0.3 to 8.0) for women. Men carrying an MSH2 mutation and their first degree relatives were at highest risks: CR70 for bladder and upper urinary tract cancer being 12.3% (95% CI 4.3% to 20.3%) and 5.9% (95% CI 0.7% to 11.1%). Bladder cancer tissue was MSI positive in 6/7 tumours and loss of IHC staining was found in 14/17 tumours, indicating Lynch syndrome aetiology. Conclusion: Patients with Lynch syndrome carrying an MSH2 mutation are at increased risk of urinary tract cancer including bladder cancer. In these cases surveillance should be considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Syngal, S., Brand, R. E., Church, J. M., Giardiello, F. M., Hampel, H. L., & Burt, R. W. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.435 · Cited by 1,662
Epidemiology of Bladder Cancer
Saginala, K., Barsouk, A., Aluru, J. S., Rawla, P., Padala, S. A., & Barsouk, A. (2020) · Medical Sciences · doi:10.3390/medsci8010015 · Cited by 838
Vasen, H. F. A., Blanco, I., Aktan-Collan, K., Gopie, J. P., Alonso, A., Aretz, S., Bernstein, I., Bertario, L., Burn, J., Capella, G., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-304356 · Cited by 746
Giardiello, F. M., Allen, J. I., Axilbund, J. E., Boland, C. R., Burke, C. A., Burt, R. W., Church, J. M., Dominitz, J. A., Johnson, D. A., Kaltenbach, T., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.04.001 · Cited by 558
Dyrskjøt, L., Hansel, D. E., Efstathiou, J. A., Knowles, M. A., Galsky, M. D., Teoh, J., & Theodorescu, D. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00468-9 · Cited by 544
Giardiello, F. M., Allen, J. I., Axilbund, J. E., Boland, R. C., Burke, C. A., Burt, R. W., Church, J. M., Dominitz, J. A., Johnson, D. A., Kaltenbach, T., et al. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.186 · Cited by 483
van Hoogstraten, L. M. C., Vrieling, A., van der Heijden, A. G., Kogevinas, M., Richters, A., & Kiemeney, L. A. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00744-3 · Cited by 375
Self-citationEpidemiology, Screening, and Prevention of Bladder Cancer
Lobo, N., Afferi, L., Moschini, M., Mostafid, H., Porten, S., Psutka, S. P., Gupta, S., Smith, A. B., Williams, S. B., & Lotan, Y. (2022) · European Urology Oncology · doi:10.1016/j.euo.2022.10.003 · Cited by 372
Risks of Less Common Cancers in Proven Mutation Carriers With Lynch Syndrome
Engel, C., Loeffler, M., Steinke, V., Rahner, N., Holinski-Feder, E., Dietmaier, W., Schackert, H. K., Goergens, H., von Knebel Doeberitz, M., Goecke, T. O., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.2278 · Cited by 306
Self-citationRisk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study
Kempers, M. J., Kuiper, R. P., Ockeloen, C. W., Chappuis, P. O., Hutter, P., Rahner, N., Schackert, H. K., Steinke, V., Holinski-Feder, E., Morak, M., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70265-5 · Cited by 295
Self-citationRisks of Primary Extracolonic Cancers Following Colorectal Cancer in Lynch Syndrome
Win, A. K., Lindor, N. M., Young, J. P., Macrae, F. A., Young, G. P., Williamson, E., Parry, S., Goldblatt, J., Lipton, L., Winship, I., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs351 · Cited by 254
Adrenocortical carcinoma, an unusual extracolonic tumor associated with Lynch II syndrome
Medina-Arana, V., Delgado, L., González, L., Bravo, A., Díaz, H., Salido, E., Riverol, D., González-Aguilera, J. J., & Fernández-Peralta, A. M. (2011) · Familial Cancer · doi:10.1007/s10689-010-9416-8 · Cited by 36
Metadata
- Authors
- van der Post, R. S., Kiemeney, L. A., Ligtenberg, M. J. L., Witjes, J. A., Hulsbergen-van de Kaa, C. A., Bodmer, D., Schaap, L., Kets, C. M., van Krieken, J. H. J. M., & Hoogerbrugge, N.
- Venue
- Journal of Medical Genetics
- Publisher
- BMJ
- Published
- 2010-06-30
- Volume
- 47
- Issue
- 7
- Pages
- 464-470
- ISSN
- 0022-2593 (ISSN-L)
- 1468-6244
- OpenAlex
- W2108496206
- Cited by
- 197
- References
- 0
- FWCI
- 6.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.